Kornimate/medical-research-clean huggingface dataset:
efficacy of l-menthol on breathlessness in chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: the purpose of this study is to assess the effect of l-menthol on breathlessness in patients with chronic obstructive pulmonary disease (copd).

breathelssness (dyspnea) is a cardinal symptom in patients with chronic obstructive pulmonary disease (copd), often triggered by daily-life physical activities. despite optimal treatment of the underlying disease, many patients still suffer from chronic and disabling dyspnea for many years, leading to exercise intolerance, and worse morbidity and mortality. to date, an effective pharmacologic treatment to relieve chronic dyspnea is lacking. recent pilot data support that inhaled l-menthol can markedly decrease laboratory-induced dyspnea in copd patients, likely through increased afferent feedback of airflow in the airways by inducing a cooling sensation through olfactory stimulation. the aim of this study is therefore to assess the effectiveness and mechanisms of inhaled menthol for relief of chronic dyspnea in patients with copd.

Eligibility criteria:
inclusion criteria: * the subject has given written consent to participate in the study * diagnosis of copd confirmed by spirometry and a fev1 \< 80% of predicted post bronchodilator at baseline * age 18 years or older * able to cycle * able to understand and talk swedish to participate in the study procedures, as judged by the investigator. exclusion criteria: * resting peripheral oxygen saturation (spo2) \< 92% * hospitalization or clinical instability during the last four weeks * treatment with supplementary oxygen at rest or during exercise * contraindication to exercise testing in accordance with clinical practice guidelines * expected survival shorter than six months as judged by the investigator * medical conditions including congestive heart failure, acute coronary artery disease, neuromuscular diseases, severe psychiatric illness, and olfaction disorder.
efficacy of the electronic acupuncture shoes: a clinical trial for chronic low back pain

Conditions: Low Back Pain

Summary: this randomized , double-blind, parallel-arm clinical trial was designed to study the efficacy and safety of the "electronic acupuncture shoes" treatment on chronic low back pain patients. chronic low back pain patients, aged 20-60, of both gender were recruited. as the primary outcome measure to assess the efficacy, "0-10 numerical rating scale" was used. secondary outcome measure included the speed of pain-relief. the number of samples in the experimental group and the control group ratio of 1 : 1 , is expected to total effective sample number is 60 . experimental group will receive a six-week "electronic acupuncture shoes" treatment and a week back to the clinic three times , subject to a total of 18 treatments , each course of about one hour . subjects will take nsaid placebo in the first week of the course of treatment . after the second week of nsaid placebo on disabled. control subjects will also accept the six- week treatment , control subjects will be equally back to the clinic three times a week , each group will be given to the subject of one hour each shoe pseudo electrotherapy treatment group and control group run by entering from the test day in the first week of the course , each taking ibuprofen 400mg, taken three times a day , the second week after the nsaid drugs on disabled.


Eligibility criteria:
inclusion criteria: a. diagnosed with chronic low back pain (pain that persists for more than 12 weeks ). b. subjects who agreed to be involved and signed the agreement, after being explained to by the investigators. exclusion criteria: a. diagnosed with cancer . b. early menopause ( before age 50 ) . c. ovariectomized d. under steroid therapy e. rheumatoid arthritis f. with fractures or have undergone back surgery. g. compression syndrome: e.g. hivd ( herniated intervertebral disc) , spinal disorder . h. renal calculus. i. pacemaker users . j. pregnant women or women who expect to be pregnant. k. visual impairment . l. diabetes. m. visceral infections, e.g. pancreatitis, nephritis . n. under other clinical trials (under medication or given other treatment) within 30 days before . o. contraindications of ibuprofen. p. poor function of heart, liver, gi tract or kidney. q. be suspected by the doctors of potential illness, disease or any other reason, which may endanger the subjects .
phase iii study investigating the efficacy and safety of ruxolitinib in early myelofibrosis patients with high molecular risk mutations.

Conditions: Myelofibrosis With High Molecular Risk Mutations

Summary: myelofibrosis patients with high molecular risk mutations have an intrinsically aggressive disease with increased risk of leukemic transformation and reduced overall survival. as there are no therapies currently established in the subset of high molecular risk patients with early myelofibrosis, the study aimed to evaluate ruxolitinib in this patient population.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of mf with bone marrow fibrosis of at least grade 1; irrespective of jak2 mutational status * patients with at least one mutation in one of the five hmr genes (asxl1, ezh2, srsf2 and idh1/2) * patients with non-palpable spleen or spleen palpable ≤ 5 cm from the left costal margin to the point of greatest splenic protrusion * patients with mf-7 score of ≤ 15, with each individual symptom score of ≤ 3 exclusion criteria: * patients with prior treatment with ruxolitinib or other jak inhibitors.

Keywords: early myelofibrosis high molecular risk mutations. ruxolitinib inc424 high molecular risk mutations hmr
multifidus & gastrocnemius muscle thickness & postural stability in spinal cord injury patients: a correlational study

Conditions: Spinal Cord Injuries

Summary: this study aims to investigate the relationship between multifidus and gastrocnemius muscle thickness with postural stability in patients with spinal cord injury.

ultrasound imaging will be used to measure multifidus and gastrocnemius muscle thickness in patients with spinal cord injury. postural stability will be assessed using the berg balance scale, a clinical balance test consisting of 14 items that evaluate an individual's ability to maintain balance during various functional tasks such as standing unsupported, reaching forward, turning, and standing on one leg. the berg balance scale is a reliable and valid clinical balance test that is commonly used in spinal cord injury patients. statistical methods, including correlation and regression analysis, will be used to analyze the data and investigate the relationship between the multifidus and gastrocnemius muscle thickness and postural stability.

Eligibility criteria:
inclusion criteria: * patients with a confirmed diagnosis of spinal cord injury at least 6 months prior to study enrollment. * patients who are able to follow instructions and comply with study procedures. exclusion criteria: * patients with severe cognitive impairment or inability to follow instructions. * patients with other medical conditions that may affect muscle thickness or postural stability, such as parkinson's disease, multiple sclerosis, or severe osteoarthritis. * patients with contraindications for ultrasound imaging, such as pregnancy or implanted devices that may be affected by the imaging. * patients with severe motor deficits that may limit their ability to perform the study procedures. * patients who are unable to tolerate the testing procedures, such as the berg balance scale or ultrasound imaging.
continuous regional analgesia after total knee arthroplasty

Conditions: Analgesia

Summary: this prospective, comparative and double blind study is aimed to determine if normal saline or dextrose 5% in water will modify the stimulation during the insertion of the stimulating catheter used for continuous femoral and sciatic blocks in total knee replacement.

the operator is blinded to the medium fluid to expand the perineural femoral and sciatic nerves before threading in the stimulating catheter. he records all the electric data of electrolocation of nerve, which will be compared to determine whether or not a difference in intensity is found between normal saline or dextrose 5% in water.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) i and ii * male or non-pregnant female * 18 - 80 years of age * not allergic to iodine or local anesthetics * absence of abnormality of coagulation * scheduled for total knee replacement

Keywords: normal saline dextrose 5% in water neurostimulation continuous regional analgesia after total knee arthroplasty
renal denervation in patients with chronic heart failure with preserved ejection fraction

Conditions: Heart Failure With Preserved Ejection Fraction; Renal Denervation

Summary: this study aims to explore the potential of rdn as a therapy for hfpef in a prospective, multicenter, randomized, blinded, sham-controlled study.

heart failure is one of the most important diseases worldwide, with a 5-year mortality of up to 75% in symptomatic patients. while substantial progress has been made in the treatment of patients with reduced left ventricular ejection fraction (hfref), mortality for patients with heart failure and preserved ejection fraction (hfpef) remains unchanged, despite a comparable prevalence and mortality of the disease as for heart failure with reduced ejection fraction. heart failure with preserved ejection fraction has a high mortality, which is contrasted by a total absence of therapy options besides symptomatic diuretic treatment. this study aims to explore the potential of rdn as a therapy for hfpef in a prospective, multicenter, randomized, blinded, sham-controlled study.

Eligibility criteria:
inclusion criteria: 1. signs or symptoms of heart failure; 2. normal or mildly abnormal systolic lv function (lvef ≥ 50%); 3. evidence of diastolic lv dysfunction. 4. individual should fulfill the diagnostic who criteria for hypertension: sbp \> 140 mmhg and/or dbp \> 90 mmhg, and is treated with at least 2 antihypertensive drugs. this treatment is expected to be maintained for at least 6 months. using this regimen the blood pressure should be adequately controlled (\< 140/90mmhg by 24 hour ambulatory bp measurement). 5. individual is adhering to a stable drug regimen hfnef, with no changes for a minimum of 2 weeks prior to enrollment, and which is expected to be maintained for at least 6 months. exclusion criteria: 1. known secondary cause of hypertension 2. anatomy not eligible for renal denervation 3. systolic heart failure (lvef \< 50%) 4. individual has an estimated glomerular filtration rate (egfr) of \< 30ml/min/1.73m2, using the mdrd calculation. 5. individual has any serious medical condition, which in the opinion of the investigator, may adversely affect the safety and/or effectiveness of the participant or the study (i.e., patients with clinically significant peripheral vascular disease, abdominal aortic aneurysm, bleeding disorders such as thrombocytopenia, haemophilia, significant anaemia, or arrhythmias such as atrial fibrillation). 6. individual is pregnant, nursing or planning to be pregnant.
"the efficacy of exparel versus a multidrug cocktail in soft tissue tumors"

Conditions: Musculoskeletal Diseases; Soft Tissue Mass

Summary: the objective of this proposed project is to determine which local anesthetic is more efficacious for use in soft tissue tumors: exparel (liposomal bupivacaine) or a cocktail of ropivicaine, epinepherine, ketolorac and clonidine. this study will examine patients' post-operative pain levels as well as their narcotic consumption after removal of a soft tissue tumor while hospitalized and then twice daily through postoperative day 14.

in recent years, there has been a substantial push to create a post-surgical protocol consisting of multimodal analgesia across multiple surgical subspecialties to decrease narcotic consumption and cost1. the negative side effects of narcotics and their addiction potential are well understood. one of the modes of analgesia currently in use to mitigate surgical pain is some form of local anesthetic. increasing the duration of analgesia has been sought after since its inception. subsequently, longer acting anesthetics like bupivacaine have been implemented as well as supplementing their use with other drugs, such as epinephrine, to increase their effect duration and overall efficacy2. this has led to the development of liposomal bupivicaine or exparel (tm, parsippany nj etc.) exparel works by infusing liposomes in the administration of the long acting local analgesic which entrap the biologically active drug and slowly release it over a period of 72-96 hours 3-4. thus, post-operative pain can be managed via direct injection of the drug at the surgical site with upwards to four days of pain relief. exparel has been studied extensively in the surgical literature; although within orthopedics, it has been primarily in regard to arthroplasty5. there has yet to be a study to illicit the best form of post-operative pain control in the world of orthopedic oncology, specifically in soft tissue tumors. the objective of this proposed project is to determine which local anesthetic is more efficacious for use in soft tissue tumors: exparel (liposomal bupivacaine) or a cocktail of ropivicaine, epinepherine, ketolorac and clonidine. this study will examine patients' post-operative pain levels as well as their narcotic consumption after removal of a soft tissue tumor while hospitalized and then twice daily through postoperative day 14.

Eligibility criteria:
inclusion criteria: * all primary soft tissue tumors * any adult patient (over 18 years old) with a soft tissue tumor confirmed with advanced imaging. two different study groups will be examined: * those patients undergoing resection of their soft tissue tumor intraoperatively injected with exparel * those patients undergoing resection of their soft tissue tumor intraoperatively injected with the cocktail. * those two groups will be further stratified by anatomic location; upper vs lower extremity, size; tumors ≥ 10cm, tumors ≥ 5cm, tumors \< 5cm, and depth; superficial vs deep. exclusion criteria: * pediatric patients * patients without soft tissue tumors * tylenol or oxycodone allergy
biopsychosocial education and chronic low back pain

Conditions: Chronic Low Back Pain

Summary: the purpose of this study is to examine whether the biopsychosocial educational program could improve patients' health-related quality of life at 3-6-12-18-24-30 and 36 - month follow up.

little information exists on biopsychosocial educational program as a multidimensional and interdisciplinary program in which quality of life is as an outcome measure. thus this educational program designed in this study is a an outpatient program that used a health education approach to empower participants through a process of assessment, education and skill building in three dimensions of physical,mental and social that leading to improved quality of life. the purpose of this study was to examine to what extent this educational program could improve low back pain patients' hrqol.

Eligibility criteria:
inclusion criteria: * low back pain lasting more than 12 weeks with or without pain radiating to the legs. * age 18-70 years. exclusion criteria: * osteoporosis * newly operation on the back up to 2 years before the beginning of the study * fresh vertebral fracture * malignancy * infection in the back * spondylolisthesis * problem in understanding farsi language
a preliminary study of bone density in neonates

Conditions: Osteopenia Of Prematurity

Summary: the study is to measure how dense or solid the infant's bones are using a new ultrasound machine and how that density changes over time.

premature infants weighing less than 1500 gms and less than 33 weeks gestation are eligible for the study

Eligibility criteria:
inclusion criteria: * premature infants born less than 33 weeks, weighing less than 1500 gms exclusion criteria: * congenital anomalies weight greater than 1500 gms

Keywords: weakening of the bones
gynecologic extramammary paget's disease

Conditions: Extramammary Paget's Disease; Extramammary Paget Disease; Paget Disease, Extramammary; Extramammary Paget's Disease of Vulva (Diagnosis); Extramammary Paget's Disease of Vagina (Diagnosis); Extramammary Paget's Disease Vulva Invasive; Extramammary Paget's Disease of Anus (Diagnosis); Extramammary Paget's Disease of Anal Canal (Diagnosis); Extramammary Paget's Disease of Skin

Summary: in addition to evaluating treatment outcomes, tissue samples and swabs will be collected as part of this study to allow physicians to better understand extramammary paget's disease (empd). the researchers also want to learn more about the microorganisms (microbiome) that live on or near the areas of skin affected by empd, in order to better understand this condition.

this is a prospective cohort study. patients with extramammary paget's disease (empd), specifically women with vulvar/perianal paget's disease, will be identified during presentation to either the dermatology department or gynecologic surgery department at mayo clinic. during physical exam, the patients will undergo skin/rectum/vagina cultures to evaluate the microbiome in these patients. the patients will be entered into the established care pathway for empd. they will be asked to complete sexual health questionnaires including: the women's health clinical questionnaires include the menopause rating scale (mrs)1, perceived stress scale2, brief resilience scale (brs)3, lasa quality of life assessment4, female sexual function index (fsfi)5, female sexual distress scale-revised6, kansas marital satisfaction scale7, and pittsburgh sleep quality index (psqi)8. the patients will be referred to women's health clinic as part of the care pathway and will undergo preoperative genital sensory testing (gst) which measures sensation of the clitoris, vulva, and vagina. the patients will have a dermatology consultation and moh's micrographic procedure as indicated. if choosing to proceed with surgical intervention, the patients will then undergo an excisional procedure with the department of gynecologic surgery. swabs, urine and tissue will be collected prior to procedures or surgery for microbiome analysis.

Eligibility criteria:
inclusion criteria: * females * age 18 years or older * diagnosed with primary or recurrent empd of vulva and/or perianal region of the body * willing and able to provide signed informed consent exclusion criteria: * males * diagnosis of paget's disease in body areas other than vulvar or perianal region
the community united to challenge asthma

Conditions: Asthma

Summary: this study compares an asthma self-management intervention, delivered to the family and tailored to their needs and cultural beliefs, to standard asthma education on two risk factors for asthma exacerbations in high-risk puerto rican children in high school. the self-management intervention will be a series of home visits provided by puerto rican community health workers. during home visits, the family will be educated using a standard asthma core curriculum which is tailored to individual needs, strengths, and beliefs. specific aim 1 is to test the ability of this tailored community health worker self-management intervention to reduce home asthma triggers and increase medication adherence in puerto rican adolescents with asthma. specific aim 2 is to test if any changes in triggers and adherence associated with this intervention are sustained 8 months after the completion of the active intervention. another goal of the study is to build community capacity for asthma management in the target high-risk community.


Eligibility criteria:
inclusion criteria: * puerto rican * in high school * have asthma exclusion criteria: * more than 18 years old * in last year of school * mild intermittent or controlled asthma
management of paroxystic atrial fibrillation in french intensive care units

Conditions: New Onset Atrial Fibrillation; ICU Patients

Summary: the primary purpose of the study is to evaluate treatment of new onset atrial fibrillation in french icu.

atrial fibrillation (af) is a common arrhythmia in the icu and is associated with significant morbidity. however, curative treatment remains unclearly established. in fact, there are no specific recommendations for new onset atrial fibrillation in icu and only few studies have assessed this topic. the paf-icu trial is an observational, prospective, multicenter, transversal trial. the main objective is to evaluate the management of paroxytic atrial fibrillation that occur in icu. the investigators want to document 2500 episodes of paroxystic atrial fibrillation in 50 icu centers. in each center, the episodes are included consecutively until the required 50 episodes are obtained for each center. a patient can present several episodes and each episode can be included in the study. a new episode is considered as such if it occurs more than one hour after the previous episode. the follow-up period for each patient corresponds to the icu stay.

Eligibility criteria:
inclusion criteria: * age \> 18 years * patient hospitalized in icu * new onset atrial fibrillation exclusion criteria: * age \< 18 years * parturient or breast-feeding woman * persistent or permanent atrial fibrillation * patients after cardiovascular or thoracic surgery * patients with therapeutic limitations

Keywords: new onset atrial fibrillation paroxystic atrial fibrillation icu patients rate control rhythm control
acupuncture for irritable bowel syndrome patients

Conditions: Irritable Bowel Syndrome

Summary: in this study, a 14-week, single blinded, randomized controlled clinical trial will be conducted to determine whether acupuncture could have significant benefits than sham acupuncture for ibs.

this is a single blinded randomized sham controlled clinical trial with two arms. 120 ibs patients will be recruited. the study will cooperate with hong kong baptist university, and university of toronto. after a 2-week run-in period, eligible subjects will be randomly assigned to one of two arms, acupuncture (ac) arm and sham acupuncture (sac) arm. each eligible subject will go through a 2-wk run-in-period, 6-wk treatment period and follow by a 6-wk of follow-up period. five visits in total were scheduled for each subject in week 0, week 2, week 5, week 8 and week 14.

Eligibility criteria:
inclusion criteria: * fulfillment of the rome iv criteria for ibs * ibs symptom severity scale (ibs-sss) \> 75 points (a range of 0-500 points of vas on five questions) at baseline and during the 2-week run-in period * written informed consent. exclusion criteria: * pregnancy or breast-feeding * medical history of inflammatory bowel diseases, carbohydrate malabsorption, hormonal disorder, known allergies to food additives, and/or any other serious diseases * unstable medical conditions * unstable mental condition or with history of mental illness * patients who have received acupuncture treatment in last three months, or took concomitant medication with affect gastrointestinal motility or visceral sensation, such as antidiarrheal agent, antidepressant, narcotic analgesic, and anticholinergic * alcoholism or drug abuse in past 1 year * having needle phobia